Literature DB >> 26977746

Nucleoside-Sparing Regimens With Raltegravir and a Boosted Protease Inhibitor: An Unsettled Issue.

Maile Y Karris1, Sonia Jain, Vi Q Bowman, Gunter Rieg, Miguel Goicoechea, Michael P Dube, Shubha Kerkar, Carol Kemper, Catherine Diamond, Xiaoying Sun, Eric S Daar, Richard H Haubrich, Sheldon Morris.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26977746      PMCID： PMC4867124          DOI： 10.1097/QAI.0000000000000990

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  10 in total

1.  A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results.

Authors:  Michael J Kozal; Sergio Lupo; Edwin DeJesus; Jean-Michel Molina; Cheryl McDonald; Francois Raffi; Jorge Benetucci; Marco Mancini; Rong Yang; Victoria Wirtz; Lisa Percival; Jenny Zhang; Li Zhu; Dilek Arikan; Awny Farajallah; Bach-Yen Nguyen; Randi Leavitt; Donnie McGrath; Max Lataillade
Journal:  HIV Clin Trials       Date:  2012 May-Jun

2.  A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study.

Authors:  Ighovwerha Ofotokun; Anandi N Sheth; Sara E Sanford; Kirk A Easley; Neeta Shenvi; Kelly White; Molly E Eaton; Carlos Del Rio; Jeffrey L Lennox
Journal:  AIDS Res Hum Retroviruses       Date:  2012-04-20       Impact factor: 2.205

3.  Does HIV antiretroviral therapy still need its backbone?

Authors:  Manuel Battegay; Luigia Elzi
Journal:  Lancet       Date:  2014-08-04       Impact factor: 79.321

4.  Beneficial effects of a switch to a Lopinavir/ritonavir-containing regimen for patients with partial or no immune reconstitution with highly active antiretroviral therapy despite complete viral suppression.

Authors:  D L Pitrak; R Estes; R M Novak; M Linnares-Diaz; J M Tschampa
Journal:  AIDS Res Hum Retroviruses       Date:  2010-12-16       Impact factor: 2.205

Review 5.  An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults.

Authors:  John A Bartlett; Michael J Fath; Ralph Demasi; Ashwaq Hermes; Joseph Quinn; Elsa Mondou; Franck Rousseau
Journal:  AIDS       Date:  2006-10-24       Impact factor: 4.177

6.  Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.

Authors:  John M Murray; Sean Emery; Anthony D Kelleher; Matthew Law; Joshua Chen; Daria J Hazuda; Bach-Yen T Nguyen; Hedy Teppler; David A Cooper
Journal:  AIDS       Date:  2007-11-12       Impact factor: 4.177

7.  Flying in the face of resistance: antiviral-independent benefit of HIV protease inhibitors on T-cell survival.

Authors:  S R Vlahakis; G D Bren; A Algeciras-Schimnich; S A Trushin; D J Schnepple; A D Badley
Journal:  Clin Pharmacol Ther       Date:  2007-03-14       Impact factor: 6.875

8.  Raltegravir with optimized background therapy for resistant HIV-1 infection.

Authors:  Roy T Steigbigel; David A Cooper; Princy N Kumar; Joseph E Eron; Mauro Schechter; Martin Markowitz; Mona R Loutfy; Jeffrey L Lennox; Jose M Gatell; Jurgen K Rockstroh; Christine Katlama; Patrick Yeni; Adriano Lazzarin; Bonaventura Clotet; Jing Zhao; Joshua Chen; Desmond M Ryan; Rand R Rhodes; John A Killar; Lucinda R Gilde; Kim M Strohmaier; Anne R Meibohm; Michael D Miller; Daria J Hazuda; Michael L Nessly; Mark J DiNubile; Robin D Isaacs; Bach-Yen Nguyen; Hedy Teppler
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

9.  Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.

Authors:  François Raffi; Abdel G Babiker; Laura Richert; Jean-Michel Molina; Elizabeth C George; Andrea Antinori; Jose R Arribas; Jesper Grarup; Fleur Hudson; Christine Schwimmer; Juliette Saillard; Cédrick Wallet; Per O Jansson; Clotilde Allavena; Remko Van Leeuwen; Jean-François Delfraissy; Stefano Vella; Geneviève Chêne; Anton Pozniak
Journal:  Lancet       Date:  2014-08-04       Impact factor: 79.321

10.  Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study.

Authors:  Jan van Lunzen; Anton Pozniak; Jose M Gatell; Andrea Antinori; Isabelle Klauck; Oscar Serrano; Adyb Baakili; Olayemi Osiyemi; Heather Sevinsky; Pierre-Marie Girard
Journal:  J Acquir Immune Defic Syndr       Date:  2016-04-15       Impact factor: 3.731
  10 in total
  3 in total

1.  HIV viral kinetics and T cell dynamics in antiretroviral naïve persons starting an integrase strand transfer inhibitor and protease inhibitor regimen.

Authors:  Maile Y Karris; Sonia Jain; Tyler R C Day; Josué Pérez-Santiago; Miguel Goicoechea; Michael P Dubé; Xiaoying Sun; Celsa Spina; Eric S Daar; Richard H Haubrich; Sheldon Morris
Journal:  HIV Clin Trials       Date:  2017-01-30

Review 2.  Two-drug regimens for treatment of naïve HIV-1 infection and as maintenance therapy.

Authors:  Katya C Corado; Margaret R Caplan; Eric S Daar
Journal:  Drug Des Devel Ther       Date:  2018-11-01       Impact factor: 4.162

3.  Development and Validation of an Up-to-Date Highly Sensitive UHPLC-MS/MS Method for the Simultaneous Quantification of Current Anti-HIV Nucleoside Analogues in Human Plasma.

Authors:  Amedeo De Nicolò; Alessandra Manca; Alice Ianniello; Alice Palermiti; Andrea Calcagno; Micol Ferrara; Miriam Antonucci; Jessica Cusato; Valeria Avataneo; Elisa De Vivo; Stefano Bonora; Francesco Giuseppe De Rosa; Giovanni Di Perri; Antonio D'Avolio
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.